A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
[Nephrology : what's new in 2025].
Revue medicale suisse|2026|Nanchen G et al.
Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzuma…
PMID: 41540866
Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.
Obesity (Silver Spring, Md.)|2026|Lim M et al.
OBJECTIVE: Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA-approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and…
Review
PMID: 41936548
RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.
Endocrine connections|2026|Ullah H et al.
PMID: 41932355
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.
Alimentary pharmacology & therapeutics|2026|Alkhouri N et al.
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly common globally and is associated with significant morbidity and mortality, necessitating effective treatments to stop its progression. Multiple pharmacologic treatme…
Review
PMID: 41941221
Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage.
Frontiers in drug delivery|2026|Niazi S
Oral delivery of peptides and proteins has been pursued for over a century due to its noninvasive nature. Despite sustained innovation across multiple technological generations-such as enteric coatings, enzyme inhibitors, permeation enhancers, nanopa…
Review
PMID: 41939723
Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.
Drug design, development and therapy|2026|Alamgir M, Sohal A, Kowdley K
Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome, has emerged as the leading cause of chronic liver disease worldwide. Its global prevalence estimated at 38% between 2016-2019, represen…
Review
PMID: 41939431
Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.
Diabetes, metabolic syndrome and obesity : targets and therapy|2026|Cetiner S
BACKGROUND: Obesity is a chronic metabolic disease associated with substantial cardiometabolic risk and long-term morbidity. Although randomized controlled trials have demonstrated the efficacy of incretin-based therapies, real-world comparative data…
PMID: 41938643
Tirzepatide-Induced Liver Injury: A Rare Complication.
AACE endocrinology and diabetes|2026|Spaeth L et al.
BACKGROUND/OBJECTIVE: Tirzepatide is widely prescribed and generally considered safe. The objective of this report is to describe a patient with tirzepatide-induced liver injury and increase awareness of this rare complication. CASE REPORT: A 60-year…
Case Report
PMID: 41938310
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.
AACE endocrinology and diabetes|2026|Eisa N, Barood O
BACKGROUND/OBJECTIVE: Recent observational studies report conflicting evidence on whether semaglutide use is associated with non-arteritic anterior ischemic optic neuropathy (NAION). This systematic review synthesizes available evidence and criticall…
Review
PMID: 41938304
A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.
AACE endocrinology and diabetes|2026|Grennan K et al.
BACKGROUND/OBJECTIVE: Maturity-onset diabetes of the young (MODY) is a form of autosomal dominant monogenic diabetes. Sulfonylureas are the mainstay of therapy for hepatocyte nuclear factor 4A (HNF4A) MODY. Here, we present a patient with HNF4A MODY…
Case Report
PMID: 41938282
Semaglutide and Alcohol use Disorder: Breaking Free of Addiction?
Current pharmaceutical design|2026|Papaetis G, Picolos M
Alcohol use disorder (AUD) is a chronically relapsing disorder characterized by a compulsive alcohol drinking pattern, loss of control over intake, and the emergence of negative emotional states promoting alcohol dependence. It is unquestionably a ma…
PMID: 41937527
Sex-specific metabolic responses to glucagon receptor agonism and modulation of the FGF21-glucagon axis in female mice.
The Journal of physiology|2026|Merrild C et al.
Glucagon receptor agonism, particularly when combined with incretin analogues, is currently being explored as a treatment for obesity to improve cardiometabolic health, given glucagon's key role in regulating energy homoeostasis. However, male-biased…
Animal Study
PMID: 41931110
Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.
The Journal of the American Academy of Orthopaedic Surgeons|2026|Strickler I et al.
INTRODUCTION: The rapid expansion of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use for weight management and diabetes has raised perioperative questions, particularly regarding delayed gastric emptying and infection risk. Emerging real-worl…
PMID: 41930687
Semaglutide as a potential tool in pre-lung transplant weight loss optimization.
JCEM case reports|2026|Ali R et al.
Patients with end-stage lung disease go through an extensive screening process prior to transplant. Obesity and uncontrolled type 2 diabetes mellitus (T2DM) are unfavorable risk factors that lead to poor outcomes. We present the case of a 69-year-old…
Case Report
PMID: 41928866
Therapeutic Landscape Evolution: From Lifestyle Interventions to Precision Pharmacotherapy.
Clinical and molecular hepatology|2026|Bong S, Teh K, Wong V
Steatotic liver disease (SLD) is a growing global epidemic, with metabolic dysfunction-associated steatotic liver disease (MASLD) now the most common chronic liver disease worldwide and closely linked to adverse cardiovascular outcomes. Lifestyle mod…
Review
PMID: 41928627
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Nature medicine|2026|Meyhöfer S et al.
In the SELECT trial, once-weekly subcutaneous semaglutide reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes. We examined semaglutide in SE…
PMID: 41928037
Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients.
Kardiologiia|2026|Tyurina A, Kurochkina N, Yezhov M
Aim To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diab…
PMID: 41925173
Prevalence of Obesity Medications in the Military Health System: An Update from 2022.
Military medicine|2026|Corrado R et al.
INTRODUCTION: Obesity poses an increasing threat to U.S. military readiness, with over half of active-duty service members classified as overweight and up to 27% with obesity. Within the Military Health System (MHS), obesity contributes to service di…
PMID: 41894608
The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.
Current obesity reports|2026|Albor C et al.
Review
PMID: 41922811
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
European journal of medical research|2026|Zhang Y et al.
OBJECTIVES: To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes. METHODS: A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Li…
ReviewMeta-Analysis
PMID: 41582189